NeuroSense Therapeutics Ltd (NASDAQ:NRSN) price on Wednesday, June 11, rose 16.90% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.49.
A look at the stock’s price movement, the close in the last trading session was $2.13. Turning to its 52-week performance, $2.15 and $0.51 were the 52-week high and 52-week low respectively. Overall, NRSN moved 126.36% over the past month.
NeuroSense Therapeutics Ltd’s market cap currently stands at around $59.74 million, with investors looking forward to this quarter’s earnings report slated for in July.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NRSN is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
NRSN’s current price about 52.86% and 97.53% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 87.07, while 7-day volatility ratio is 5.28% and 6.48% in the 30-day chart. Further, NeuroSense Therapeutics Ltd (NRSN) has a beta value of 1.64, and an average true range (ATR) of 0.16.
If we refocus on NeuroSense Therapeutics Ltd (NASDAQ:NRSN), historical trading data shows that trading volumes averaged 209.64K over the past 3 months. The company’s latest data on shares outstanding shows there are 23.23 million shares.
The 27.54% of NeuroSense Therapeutics Ltd’s shares are in the hands of company insiders while institutional holders own 0.81% of the company’s shares. Current price change has pushed the stock 107.50% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NRSN stock continues to rise going into the next quarter.
